ABVX Abivax SA American Depositary Shares Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:35
Jul 17
Jul 17
Cryptic tweet with ticker mention, no clear directional stance or reasoning.
LOW
20:46
Jul 16
Jul 16
The author humorously reflects on missing a biotech stock's bounce after a buyout, not expressing a current position or trade idea.
LOW
12:00
Jul 16
Jul 16
The author dismisses a $2M payment to another biotech as meaningless during a known no-buyout window, treating it as a joke rather than a trade signal.
LOW
11:09
Jul 16
Jul 16
Reports development collaboration with Valerio Therapeutics and pipeline update; no directional view from speaker.
LOW
14:07
Jul 15
Jul 15
Author discloses existing long position in ABVX, expressing desire for larger exposure within the broader XBI bullish thesis of macro tailwinds and record sector M&A.
MED
17:24
Jul 14
Jul 14
Watch ABVX: author replies only 'Yes' to a buyout-price question; bullish context, but no explicit buy/hold/current position or actionable call.
MED
14:25
Jul 14
Jul 14
Buy ABVX into current weakness, which author attributes to a structural timing gap in M&A process — talks couldn't resume until last Monday and bidding takes 1-2 weeks minimum, making the dip a brief dead window before speculative buying resumes.
MED
20:04
Jul 10
Jul 10
Long ABVX as author holds position citing M&A takeout potential, drawing parallels to RNA and CINC where acquisition offers arrived rapidly; takeout valuation framework attached.
MED
19:33
Jul 07
Jul 07
Buy ABVX ahead of an anticipated near-term catalyst (described as significant news expected within weeks); author expects the current acquisition/event premium gap to compress, implying upside from current prices.
MED
20:24
Jul 06
Jul 06
The author dismisses VRTX as a potential buyer of ABVX but suggests M&A capital could rotate into ABVX, framing the news as neutral to positive without taking a personal position.
LOW
20:09
Jul 06
Jul 06
Author recommends partial profit-taking on ABVX in the $160s range given the magnitude of the prior 12-month gain, while maintaining a core long position.
MED
18:06
Jul 06
Jul 06
Hold/overweight ABVX as a significantly derisked biotech with hedge fund accumulation; author explicitly maintains position, citing lesson learned from selling winners too early in prior names, while acknowledging prudent partial trim after a big 12-month run.
MED
02:10
Jul 06
Jul 06
Buy ABVX as a compelling M&A target for JNJ; Obefazimod's superior efficacy in IBD versus JNJ's Icotyde makes ABVX either an acquisition or a franchise-threatening competitor, creating asymmetric upside.
MED
01:52
Jul 06
Jul 06
Endorses holding $ABVX as cancer concerns are debunked and efficacy data exceeded expectations, supporting continued outperformance.
MED
01:48
Jul 06
Jul 06
Buy ABVX as it materially underperforms XBI (+8% vs +20%) despite delivering what the author calls the greatest IBD readout ever — unprecedented clinical and endoscopic remission rates — while a debunked cancer signal drove the dip; active M&A talks (Reuters article + greenshoe breadcrumb) add a near-term catalyst toward $200s.
HIGH
10:30
Jul 03
Jul 03
Buy ABVX on the thesis that the current market cap better reflects the value of its drug Obefazimod, implying further upside from recent gains.
MED
00:04
Jul 03
Jul 03
Abivax shares are climbing after the biotech firm moved to bolster its balance sheet, but no forward-looking position is stated.
LOW
20:01
Jul 02
Jul 02
The tweet expresses excitement about these biotech tickers with no explicit position or directional call, so they are indexed as watch.
LOW
12:41
Jul 02
Jul 02
M&A speculation: pharma diligence on ABVX has intensified recently, and a deal could close this summer based on industry precedents.
MED
09:33
Jul 02
Jul 02
Abivax shares continue climbing after the biotech firm moves to bolster its balance sheet.
02:29
Jul 02
Jul 02
Author argues that ABVX's accelerated greenshoe closure signals imminent buyout discussions resumption, supporting a bullish M&A thesis.
02:29
Jul 02
Jul 02
Buy ABVX as the company's offering structure and Reuters sources indicate imminent resumption of buyout discussions, with due diligence already underway and catalysts from maintenance data.
MED
12:53
Jul 01
Jul 01
Buy ABVX as a 7x oversubscribed $920M offering signals exceptional institutional demand for what the author characterizes as an undervalued biotech with a breakthrough drug; heavy oversubscription typically supports post-offering price appreciation.
MED
09:26
Jul 01
Jul 01
Remain long ABVX into two near-term binary catalysts — Crohn's disease data readout (asymmetric +120%/-20% setup) and FDA labeling resolution — with M&A optionality in the 3-6 month post-readout window and ~$10B peak sales potential; recent institutional offering at $125 viewed as derisking, not dilutive.
HIGH
02:03
Jul 01
Jul 01
Reports oversubscribed offering with ~$4B demand for $600M raise, a bullish development but no personal directional commitment.
MED
00:39
Jul 01
Jul 01
Buy ABVX ahead of post-offering buying pressure: institutional buyers wall-crossed during the deal couldn't purchase shares on the open market and will now accumulate in the secondary market, creating sustained demand; speaker views the stock as "far too cheap" and expects continued rally.
HIGH
22:13
Jun 30
Jun 30
Buy ABVX; author sees open-market fair value at ~$180 with buyout scenario at ~$250, implying significant upside from current levels following a recent data update.
MED
20:56
Jun 30
Jun 30
Buy ABVX ahead of/into the $600M offering, which the author expects to be oversubscribed; prior low volume attributed to funds awaiting allocation, with a post-raise rally anticipated as the catalyst resolves.
MED
20:40
Jun 30
Jun 30
Author notes no offering for ABVX yet but expresses uncertainty with "hmm," indicating a watchful stance rather than a directional position.
LOW
19:53
Jun 30
Jun 30
Author suggests ABVX is closing like an offering is imminent, but the tweet is a speculative observation rather than an explicit position or trade call.
LOW
About ABVX Analyst Coverage
Buzzberg tracks ABVX (Abivax SA American Depositary Shares) across 10 sources. 151 bullish vs 0 bearish calls from 10 analysts. Sentiment: predominantly bullish (58%). 259 total trade ideas tracked. Past 7 days: 2 bullish, 5 watch. Latest voices: seedy19tron, A May MD, BarbarianCap.